A large randomised controlled trial has found that a structured, smartphone-based eczema education program for caregivers reduced relapse risk over the first 12 weeks for children aged 0–6 years with ...
Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease ...
A weakened skin barrier doesn’t always look obvious. Discover five subtle symptoms and the dermatologist-approved ways to ...
Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.
Dr. Murphy Rose specifically recommends this for those dealing with both sensitivity and breakouts. "For acne-prone but ...
In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...
In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has ...
New Guidance Helps Parents Understand Infant Skin Vulnerability and Bacterial Imbalance A child's eczema severity often ...
More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep, mental health, and daily ...
Delgocitinib cream and dupilumab have similar efficacy at 16 weeks of treatment in patients with moderate to severe atopic hand eczema.
Tralokinumab plus optional use of TCS or TCI in adults with moderate to severe AD was associated with stable disease control for up to 4 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback